| Item 1. | Security and Issuer |
| (a) | Title of Class of Securities:
Warrants to purchase Class A Common Stock, par value $0.0001 per share |
| (b) | Name of Issuer:
Strata Critical Medical, Inc. |
| (c) | Address of Issuer's Principal Executive Offices:
31 HUDSON YARDS, 14TH FLOOR, NEW YORK,
NEW YORK
, 10001. |
| Item 2. | Identity and Background |
|
| (a) | Velibor Krstic |
| (b) | Via Baraggie 23, 6612 Ascona, SWITZERLAND |
| (c) | Private Investor |
| (d) | NONE |
| (e) | NONE |
| (f) | SWITZERLAND |
| Item 3. | Source and Amount of Funds or Other Consideration |
| | The total amount of funds used by the Reporting Person to purchase the 764,435 Warrants reported herein was approximately $15,231. All such funds were provided from the Reporting Persons personal funds (Personal Funds). No part of the purchase price was borrowed from any bank or other third party for the purpose of acquiring, holding, trading, or voting the securities. |
| Item 4. | Purpose of Transaction |
| | The Reporting Person acquired the Warrants for investment purposes. The Reporting Person believes that the current market price of the Warrants (SRTAW) is significantly undervalued relative to the Issuer's fundamentals, particularly considering the Adjusted EBITDA of $14.1 million and the recent integration of Keystone Perfusion.
The Reporting Person intends to actively monitor the decisions of the Board of Directors and management leading up to the Warrant expiration date of May 7, 2026. The Reporting Person may engage in discussions with the Issuer, its Sponsor (KSL Capital Partners), and other relevant shareholders to discuss options aimed at maximizing the value of the investment, including, but not limited to, the implementation of a voluntary Exchange Offer or an amendment to the Warrant Agreement.
Except as set forth above, the Reporting Person has no current plans or proposals that relate to or would result in any of the actions listed in paragraphs (a) through (j) of Item 4 of Schedule 13D. |
| Item 5. | Interest in Securities of the Issuer |
| (a) | The Reporting Person beneficially owns 764,435 Warrants, which represent approximately 8.3% of the 9,166,644 public warrants outstanding. This percentage is based on the number of Public Warrants reported by the Issuer in its most recent Annual Report on Form 10-K. |
| (b) | The Reporting Person has the sole power to vote or to direct the vote, and the sole power to dispose or to direct the disposition of, all 764,435 Warrants reported in Item 5(a). |
| (c) | During the past 60 days, the Reporting Person acquired an aggregate of 764,435 Warrants in open market transactions on the Nasdaq Stock Market for an aggregate purchase price of approximately $15,231. The most recent transaction, which resulted in the Reporting Person becoming the beneficial owner of more than 5% of the class, occurred on April 1, 2026. |
| (d) | No other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Warrants reported herein. |
| (e) | Not applicable |
| Item 6. | Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer |
| | To the best knowledge of the Reporting Person, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the person named in Item 2 and between such person and any person with respect to any securities of the Issuer, including but not limited to, transfer or voting of any of the securities, finders fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies. |
| Item 7. | Material to be Filed as Exhibits. |
| | NONE |
